-
RGX-202 gene therapy meets main goal in Phase 3 DMD clinical trial
The Phase 3 portion of a clinical trial testing RGX-202, an investigational gene therapy for
-
When it comes to raising a child with DMD, the third time is not the charm
They say the third time is the charm. However, as a mom to three sons
-
NEW: Livestream with the PAAC
What can you learn from the PPMD Adult Advisory Committee (PAAC) that you can’t ask Google?
-
MDA taps Bridgebio funding to improve LGMD care coordination
Bridgebio is providing $100,000 to the Muscular Dystrophy Association (MDA) to advance projects aimed at
-
RegenXBio announces positive topline results from pivotal Phase 3 microdystrophin gene therapy trial
RegenXBio shared positive topline results from their pivotal Phase 3 AFFINITY DUCHENNE study of RGX-202
-
REGENXBIO Shares Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
REGENXBIO Inc. has announced positive topline and interim functional data from the pivotal Phase III
-
GEMMABio Announces Duchenne Muscular Dystrophy Program, Shares Preclinical Data for Investigational Gene Therapy for Duchenne
Today, Gemma Biotherapeutics (GEMMABio), a clinical‑stage, global, genetic therapeutics company, shared information about the company’s
-
MDA Ambassador Guest Blog: Embers of Resilience Through Depression
Joshua Vinson enjoys rain, camping, and cooking. Joshua works as a Quality Assurance Specialist in
-
When it comes to accessibility, even the best-laid plans can go awry
On May 1, my daughter Jill graduated from the University of Pittsburgh with a master’s
-
Clinical Research Alert: Natural History Study in Individuals with Myotonic Dystrophy Type 2
Researchers at the University of Rochester are seeking adults with myotonic dystrophy type 2 (DM2) for
